EP0822820A1 - NEUE VERWENDUNG VON (S)-ADENOSYL-L-METHIONIN (SAMe) - Google Patents
NEUE VERWENDUNG VON (S)-ADENOSYL-L-METHIONIN (SAMe)Info
- Publication number
- EP0822820A1 EP0822820A1 EP96913500A EP96913500A EP0822820A1 EP 0822820 A1 EP0822820 A1 EP 0822820A1 EP 96913500 A EP96913500 A EP 96913500A EP 96913500 A EP96913500 A EP 96913500A EP 0822820 A1 EP0822820 A1 EP 0822820A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- same
- patient
- day
- methionine
- doses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000028867 ischemia Diseases 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 230000001960 triggered effect Effects 0.000 claims abstract description 3
- 230000006378 damage Effects 0.000 claims description 8
- 229960004452 methionine Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002253 anti-ischaemic effect Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010001526 Air embolism Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010052346 Brain contusion Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000009516 brain contusion Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- FUDAIDRKVVTJFF-UHFFFAOYSA-N butane-1,1-disulfonic acid Chemical compound CCCC(S(O)(=O)=O)S(O)(=O)=O FUDAIDRKVVTJFF-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- SAMe (S) -Adenosyl-L-methionine (SAMe) and its salts are already known, cf. EP-PS 162.323. It is also described that SAMe has a principal anti-ischemic effect (Eur. J. Pharmacol. 144: 211, 1987; Jpn. J. Pharmacol. 46: 225, 1988; Eur. J. Pharmacol. 166: 231, 1989; Jpn J. Pharmacol. 52: 141, 195 * 0). According to JP-PS 1,686,947, SAMe can be used for various indications relating to central damage. Daily doses of 100 mg to 1550 mg are given in this publication.
- J. Pharmacol. 49, 119-124 (1989) describes the effect of SAMe on the Ca content and glucose metabolism and on mortality in rats after transient ischemia at doses of 100 mg / kg.
- Acute embolic ischemia e.g. cardiac embolism, fatty
- Thrombotic ischemia which includes the so-called cerebral
- Ischemia Ischemias triggered by immunological, inflammatory mechanisms. This also includes focal ischemia caused by hemostasiological and immunological system diseases - focal ischemia, which are associated with special forms of vascular processes and other unusual causes. Traumatic brain and spinal injuries that lead directly or indirectly to focal ischemia (such as bulky intracerebral, subdural, ⁇ pidural ⁇ 'bleeding, brain contusions and laceration).
- SAMe is preferably used in the form of a salt with a physiologically acceptable acid.
- Preferred acids are: hydrochloric acid, sulfuric acid, phosphoric acid, formic acid, acetic acid, citric acid, tartaric acid, methanesulfonic acid, p-toluenesulfonic acid and butanedisulfonic acid.
- SAMe or its salts are provided or recommended for the above-mentioned indication in an amount of at least 2000 mg / day / patient, in particular at least 3000 mg / day / patient and preferably in doses of at least 7000 mg / day / patient.
- the indication of the high dose according to the invention is an essential lesson in the obvious preparation of the drug.
- SAMe is administered parenterally (intravenously, intraarterially or intramuscularly) in a customary manner, with intravenous administration being the preferred form of administration.
- the above amount can be infused into the patient over a period of 1 to 24 hours for several days.
- Application forms which contain 6-18% by weight of SAMe together with lysine in water are particularly suitable for the use according to the invention.
- Such an application form can, for example, be the following Composition: 400 mg SAMe, 324.3 mg L-lysine, 11.5 mg NaOH and 472.1 mg water for injections.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19515275A DE19515275A1 (de) | 1995-04-26 | 1995-04-26 | Neue Verwendung von (S)-Adenosyl-L-methionin(SAMe) |
| DE19515275 | 1995-04-26 | ||
| PCT/EP1996/001570 WO1996033727A1 (de) | 1995-04-26 | 1996-04-13 | NEUE VERWENDUNG VON (S)-ADENOSYL-L-METHIONIN (SAMe) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0822820A1 true EP0822820A1 (de) | 1998-02-11 |
Family
ID=7760373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP96913500A Withdrawn EP0822820A1 (de) | 1995-04-26 | 1996-04-13 | NEUE VERWENDUNG VON (S)-ADENOSYL-L-METHIONIN (SAMe) |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0822820A1 (no) |
| JP (1) | JPH11504023A (no) |
| KR (1) | KR19990008061A (no) |
| CN (1) | CN1182367A (no) |
| AR (1) | AR001687A1 (no) |
| AU (1) | AU5646396A (no) |
| CA (1) | CA2216854A1 (no) |
| CZ (1) | CZ330597A3 (no) |
| DE (1) | DE19515275A1 (no) |
| HR (1) | HRP960196A2 (no) |
| IL (1) | IL117844A0 (no) |
| MX (1) | MX9707735A (no) |
| NO (1) | NO974941L (no) |
| WO (1) | WO1996033727A1 (no) |
| ZA (1) | ZA963296B (no) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE37913B1 (en) * | 1972-08-02 | 1977-11-09 | Bioresearch Sas | Salt of s-adenosyl-l-methionine |
| JPS59139319A (ja) * | 1983-01-31 | 1984-08-10 | Fuji Kagaku Kogyo Kk | 脳障害による身体機能障害治療剤 |
| JPH02290896A (ja) * | 1989-04-28 | 1990-11-30 | Fuji Kagaku Kogyo Kk | 新規なｓ―アデノシルメチオニン誘導体 |
| DE4425280C2 (de) * | 1994-07-16 | 1997-05-07 | Knoll Ag | Verwendung von (S)-Adenosyl-L-methionin und dessen physiologisch verträglichen Salzen zur Behandlung von Reperfusionsschäden, die nach temporärer fokaler Ischämie ausgelöst werden |
-
1995
- 1995-04-26 DE DE19515275A patent/DE19515275A1/de not_active Withdrawn
-
1996
- 1996-04-08 IL IL11784496A patent/IL117844A0/xx unknown
- 1996-04-13 AU AU56463/96A patent/AU5646396A/en not_active Abandoned
- 1996-04-13 MX MX9707735A patent/MX9707735A/es unknown
- 1996-04-13 JP JP8532131A patent/JPH11504023A/ja active Pending
- 1996-04-13 CN CN96193498A patent/CN1182367A/zh active Pending
- 1996-04-13 CZ CZ973305A patent/CZ330597A3/cs unknown
- 1996-04-13 WO PCT/EP1996/001570 patent/WO1996033727A1/de not_active Application Discontinuation
- 1996-04-13 CA CA002216854A patent/CA2216854A1/en not_active Abandoned
- 1996-04-13 EP EP96913500A patent/EP0822820A1/de not_active Withdrawn
- 1996-04-13 KR KR1019970707585A patent/KR19990008061A/ko not_active Application Discontinuation
- 1996-04-23 AR AR33625596A patent/AR001687A1/es unknown
- 1996-04-24 HR HR19515275.1A patent/HRP960196A2/hr not_active Application Discontinuation
- 1996-04-25 ZA ZA9603296A patent/ZA963296B/xx unknown
-
1997
- 1997-10-24 NO NO974941A patent/NO974941L/no unknown
Non-Patent Citations (1)
| Title |
|---|
| See references of WO9633727A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| NO974941D0 (no) | 1997-10-24 |
| AR001687A1 (es) | 1997-11-26 |
| ZA963296B (en) | 1997-10-27 |
| NO974941L (no) | 1997-10-24 |
| AU5646396A (en) | 1996-11-18 |
| KR19990008061A (ko) | 1999-01-25 |
| JPH11504023A (ja) | 1999-04-06 |
| HRP960196A2 (en) | 1998-02-28 |
| CZ330597A3 (cs) | 1998-02-18 |
| CA2216854A1 (en) | 1996-10-13 |
| WO1996033727A1 (de) | 1996-10-31 |
| MX9707735A (es) | 1997-12-31 |
| CN1182367A (zh) | 1998-05-20 |
| DE19515275A1 (de) | 1996-10-31 |
| IL117844A0 (en) | 1996-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69822665T2 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| DE3413052A1 (de) | Pharmazeutische zubereitung und deren verwendung zur behandlung von hauterkrankungen | |
| DE69529156T2 (de) | Verwendung von amino-hydrierten chinazolinverbindungen und ihren derivaten zur entwöhnung bei drogenabhängigkeit | |
| DE3317692A1 (de) | Verwendung von metkephamid oder eines pharmazeutisch unbedenklichen salzes hiervon als analgetikum bei traechtigen weiblichen tieren und insbesondere bei schwangeren frauen | |
| DE69232516T2 (de) | Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende Verbindung | |
| DE69834638T2 (de) | Zusammensetzung zur Behandlung von Augenhypertension oder Glaukom | |
| DE69328792T2 (de) | Behandlung von migräne | |
| EP0108820A1 (de) | Infusionslösungen zur Herztherapie | |
| DE69303015T2 (de) | Verwendung von phenothiazin-derivaten zur behandlung der ischämie und/oder der hypoxämie | |
| DE2514335C3 (de) | Oral zu verabreichendes Arzneimittel mit Antiplasmin-Inhibitorwirkung | |
| DE69110615T2 (de) | Verwendung von Aminosäuren zum Schutz von ischemischem Herzgewebe und dessen metabolischer Wiederherstellung. | |
| DE3643119A1 (de) | Therapeutische zusammensetzung fuer diabetes-komplikationen | |
| DE60207442T2 (de) | VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTION | |
| DE4425280C2 (de) | Verwendung von (S)-Adenosyl-L-methionin und dessen physiologisch verträglichen Salzen zur Behandlung von Reperfusionsschäden, die nach temporärer fokaler Ischämie ausgelöst werden | |
| EP0132595B1 (de) | Tokolytisches Mittel | |
| DE2750159C3 (de) | Infusionslösung zur Behandlung von hepatischer Encephalopathie und ein Verfahren zu deren Herstellung | |
| EP0350738A2 (de) | (S)-Emopamil zur Anwendung bei der Behandlung von Migräne | |
| DE2611976A1 (de) | Pharmazeutisches praeparat zur besserung und wiederherstellung bei verminderten bewusstseinszustaenden | |
| WO1996033727A1 (de) | NEUE VERWENDUNG VON (S)-ADENOSYL-L-METHIONIN (SAMe) | |
| DE2131679A1 (de) | 3,4,5-Trimethoxybenzamidocarbonsaeure und ihre Salze sowie Arzneipraeparate | |
| EP0013962A1 (de) | Aminosäuren und Mineralsalze enthaltende Infusionslösung | |
| DE69808455T2 (de) | Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen | |
| DE69909395T2 (de) | Zusammensetzung mit ketanserin und carnitin zur behandlung von crps | |
| EP0845264A1 (de) | Teil- oder Vollextrakt aus nicht fermentierter Camellia sinensis L. | |
| DE60012183T2 (de) | Verwendung einer makrolid-verbindung zur herstellung eines medikaments zur behandlung von gehirnschäden aufgrund von ischämie oder blutungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19970919 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE ES FI FR GB IT LI NL SE |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19991103 |